Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies.
blood test
brain tumour
central nervous system
circulating glial cells
diagnosis
glial malignancy
liquid biopsy
non-invasive
triaging
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
revised:
17
11
2023
received:
03
08
2023
accepted:
29
11
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
Here, we describe a blood test for the detection of glial malignancies (GLI-M) based on the identification of circulating glial cells (CGCs). The test is highly specific for GLI-M and can detect multiple grades (II-IV) and subtypes including gliomas, astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas, irrespective of gender and age. Analytical validation of the test was performed as per Clinical and Laboratory Standards Institute (CLSI) guidelines. Real-world performance characteristics of the test were evaluated in four clinical (observational) studies. The test has high analytical sensitivity (95%), specificity (100%) and precision (coefficient of variation [CV] = 13.7% for repeatability and CV = 23.5% for within laboratory precision, both at the detection threshold) and is not prone to interference from common drugs and serum factors. The ability of the test to detect and differentiate GLI-M from non-malignant brain tumours (NBT), brain metastases from primary epithelial malignancies (EPI-M) and healthy individual donors (HD) was evaluated in four clinical cohorts. Across these clinical studies, the test showed 99.35% sensitivity (95% confidence interval [CI]: 96.44%-99.98%) and 100% specificity (95% CI: 99.37%-100%). The performance characteristics of this test support its clinical utility for diagnostic triaging of individuals presenting with intracranial space-occupying lesions (ICSOL).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Datar Cancer Genetics Private Limited
Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Cancer.Net. Brain Tumor: Statistics. Accessed November 30, 2023. https://www.cancer.net/cancer-types/brain-tumor/statistics
Cancer Stat Facts: Brain and Other Nervous System Cancer. Accessed November 30, 2023. https://seer.cancer.gov/statfacts/html/brain.html
Miller K, Ostrom Q, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381-406. doi:10.3322/caac.21693
Malone H, Yang J, Hershman DL, Wright JD, Bruce JN, Neugut AI. Complications following stereotactic needle biopsy of intracranial tumors. World Neurosurg. 2015;84(4):1084-1089. doi:10.1016/j.wneu.2015.05.025
Koszewski W, Kroh H, Kunert P. Trudności w biopsjach stereotaktycznych guzów mózgu [Difficulties in stereotactic biopsies of brain tumors]. Neurol Neurochir Pol. 2002;36(3):481-488. Polish.
Ramkissoon L, Pegram W, Haberberger J, et al. Genomic profiling of circulating tumor DNA from cerebrospinal fluid to guide clinical decision making for patients with primary and metastatic brain tumors. Front Neurol. 2020;19(11):544680. doi:10.3389/fneur.2020.544680
Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nat Med. 2020;26(7):1044-1047. doi:10.1038/s41591-020-0932-2
Ebrahimkhani S, Vafaee F, Hallal S, et al. Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. npj Precis Oncol. 2018;12(2):28. doi:10.1038/s41698-018-0071-0
Pickles J, Fairchild A, Stone T, et al. DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. Lancet Child Adolesc Health. 2020;4(2):121-130. doi:10.1016/S2352-4642(19)30342-6
Macarthur K, Kao G, Chandrasekaran S, et al. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014;74(8):2152-2159. doi:10.1158/0008-5472.CAN-13-0813
Müller C, Holtschmidt J, Auer M, et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6:247ra101. doi:10.1126/scitranslmed.3009095
Kan L, Drummond K, Hunn M, et al. Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis. BMJ Neurol Open. 2020;2(2):e000069. doi:10.1136/bmjno-2020-000069
Akolkar D, Patil D, Crook T, et al. Circulating ensembles of tumor-associated cells: a redoubtable new systemic hallmark of cancer. Int J Cancer. 2020;146(12):3485-3494. doi:10.1002/ijc.32815
Ranade A, Bhatt A, Page R, et al. Hallmark circulating tumor-associated cell clusters signify 230 times higher one-year cancer risk. Cancer Prev Res (Phila). 2021;14(1):11-16. doi:10.1158/1940-6207.CAPR-20-0322
Gaya A, Crook T, Plowman N, et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol. 2021;129(3):226-238. doi:10.1002/cncy.22366
von Elm E, Altman D, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD
Crook T, Gaya A, Page R, et al. Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors. Cancer Chemother Pharmacol. 2021;87(2):197-205. doi:10.1007/s00280-020-04189-8
CLSI. Evaluation of Linearity of Quantitative Measurement Procedures. CLSI Guideline EP06. 2nd ed. Clinical and Laboratory Standards Institute; 2020.
CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures. Approved Guideline. CLSI Document EP17-A2. 2nd ed. Clinical and Laboratory Standards Institute; 2012.
CLSI. Evaluation of Precision of Quantitative Measurement Procedures. Approved Guideline. CLSI Document EP05-A3. 3rd ed. Clinical and Laboratory Standards Institute; 2014.
Hamilton J, Rapp M, Schneiderhan T, et al. Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escape. J Clin Oncol. 2014;32(22):e80-e84. doi:10.1200/JCO.2013.48.7546
Pasquier B, Pasquier D, N'Golet A, et al. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer. 1980;45(1):112-125. doi:10.1002/1097-0142(19800101)45:1<112::aid-cncr2820450121>3.0.co;2-9
Chang H, Ding Y, Wang P, Wang Q, Lin Y, Li B. Cutaneous metastases of the glioma. J Craniofac Surg. 2018;29(1):e94-e96. doi:10.1097/SCS.0000000000004204
Pérez-Bovet J, Rimbau-Muñoz J. Glioblastoma multiforme metastases to the masticator muscles and the scalp. J Clin Neurosci. 2018;53:237-239. doi:10.1016/j.jocn.2018.04.021
Rosen J, Blau T, Grau SJ, Barbe MT, Fink GR, Galldiks N. Extracranial metastases of a cerebral glioblastoma: a case report and review of the literature. Case Rep Oncol. 2018;11(2):591-600. doi:10.1159/000492111
Eibl RH, Schneemann M. Liquid biopsy and primary brain tumors. Cancers (Basel). 2021;13(21):5429. doi:10.3390/cancers13215429
Zhang H, Yuan F, Qi Y, Liu B, Chen Q. Circulating tumor cells for glioma. Front Oncol. 2021;11:607150. doi:10.3389/fonc.2021.607150
Bang-Christensen S, Pedersen R, Pereira M, et al. Capture and detection of circulating glioma cells using the recombinant VAR2CSA malaria protein. Cell. 2019;8(9):998. doi:10.3390/cells8090998
Sullivan J, Nahed B, Madden M, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4(11):1299-1309. doi:10.1158/2159-8290.CD-14-0471
Gao F, Cui Y, Jiang H, et al. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016;7(44):71330-71340. doi:10.18632/oncotarget.11114
Krol I, Castro-Giner F, Maurer M, et al. Detection of circulating tumour cell clusters in human glioblastoma. Br J Cancer. 2018;119(4):487-491. doi:10.1038/s41416-018-0186-7
Crook T, Leonard R, Mokbel K, et al. Accurate screening for early-stage breast cancer by detection and profiling of circulating tumor cells. Cancers (Basel). 2022;14(14):3341. doi:10.3390/cancers14143341
Limaye S, Chowdhury S, Rohatgi N, et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023;12(8):9116-9127. doi:10.1002/cam4.5649
Fazeny-Dörner B, Wenzel C, Veitl M, et al. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs. 2003;14(4):305-312. doi:10.1097/00001813-200304000-00008
Air E, Warnick R, McPherson C. Management strategies after nondiagnostic results with frameless stereotactic needle biopsy: retrospective review of 28 patients. Surg Neurol Int. 2012;3(Suppl 4):S315-S319. doi:10.4103/2152-7806.103026
Woodworth G, McGirt M, Samdani A, et al. Frameless image-guided stereotactic brain biopsy procedure: diagnostic yield, surgical morbidity, and comparison with the frame-based technique. J Neurosurg. 2006;104(2):233-237. doi:10.3171/jns.2006.104.2.233
Khatab S, Spliet W, Woerdeman P. Frameless image-guided stereotactic brain biopsies: emphasis on diagnostic yield. Acta Neurochir. 2014;156(8):1441-1450. doi:10.1007/s00701-014-2145-2
Füreder L, Widhalm G, Gatterbauer B, et al. Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. Clin Exp Metastasis. 2018;35(8):727-738. doi:10.1007/s10585-018-9947-1
Louis D, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106
Kolostova K, Pospisilova E, Pavlickova V, et al. Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Am J Transl Res. 2021;13(5):4489-4499.